Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 11/20 | 0.66 |
| ▸ | PLA2G4B | P0C869 | 7/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2803691 | 0.93 | PLA2G4A (0.68) | PLA2G4A | |
| SCHEMBL3922464 | 0.85 | PLA2G4A (0.68) | PLA2G4A | |
| SCHEMBL3927639 | 0.83 | PLA2G4B (0.60) | PLA2G4APLA2G4BTP53TSHR | |
| SCHEMBL3927580 | 0.80 | PLA2G4A (1.00) | PLA2G4APLA2G4B | |
| SCHEMBL3922402 | 0.80 | PLA2G4A (0.72) | PLA2G4A | |
| SCHEMBL27650181 | 0.79 | PLA2G4A (0.70) | PLA2G4A | |
| SCHEMBL3919688 | 0.76 | PLA2G4A (0.52) | PLA2G4APLA2G4B | |
| SCHEMBL3688521 | 0.76 | PLA2G4B (1.00) | PLA2G4APLA2G4BTP53TSHR | |
| SCHEMBL4490212 | 0.73 | PLA2G4A (0.68) | PLA2G4A | |
| SCHEMBL3929904 | 0.73 | PLA2G4A (0.79) | PLA2G4APLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608633-B2 | Heteroaryl-substituted acetone derivatives as inhibitors of phospholipase A2 | MERCKLE GMBH (DE) | 2009-10-27 | — | — | US | disclosed |
| EP-1590324-B1 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVES AS INHIBITORS OF PHOSPHOLIPASE A sb 2 /sb | MERCKLE GMBH (DE) | 2009-03-11 | — | — | EP | disclosed |
| US-20060142366-A1 | Novel heteroaryl-substituted acetone derivatives as inhibitors of phospholipase a2 | MERCKLE GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
| EP-1590324-A1 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVES AS INHIBITORS OF PHOSPHOLIPASE A sb 2 /sb | MERCKLE GMBH (DE) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004069797-A1 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVES AS INHIBITORS OF PHOSPHOLIPASE A2 | MERCKLE GMBH (DE) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142366-A1 | Novel heteroaryl-substituted acetone derivatives as inhibitors of phospholipase a2 | PLD2, PLA2G1B, PLA2G4A | PLA2G4A 3/4885PLA2G4B 4/4885TP53 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.